| Nome |
# |
|
Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients, file e0d6c92b-c018-fcf8-e053-d805fe0aa794
|
420
|
|
A new validated HPLC-UV method for therapeutic monitoring of daptomycin in comparison with reference Mass Spectrometry, file e0d6c92e-71c6-fcf8-e053-d805fe0aa794
|
314
|
|
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life, file e0d6c929-fdd5-fcf8-e053-d805fe0aa794
|
220
|
|
Appropriateness of repetitive therapeutic drug monitoring and laboratory turn around time, file e0d6c92c-dcd6-fcf8-e053-d805fe0aa794
|
214
|
|
EPMA position paper in cancer: Current overview and future perspectives, file e0d6c927-3839-fcf8-e053-d805fe0aa794
|
207
|
|
Pathophysiology and pharmacological targets of VEGF in diabetic macular edema, file e0d6c927-b49c-fcf8-e053-d805fe0aa794
|
206
|
|
Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer, file e0d6c92b-37cb-fcf8-e053-d805fe0aa794
|
203
|
|
Precision medicine in lymphoma by innovative instrumental platforms, file e0d6c92e-107d-fcf8-e053-d805fe0aa794
|
144
|
|
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients, file e0d6c931-1d35-fcf8-e053-d805fe0aa794
|
144
|
|
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment, file e0d6c92a-650f-fcf8-e053-d805fe0aa794
|
126
|
|
Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients, file e0d6c927-4527-fcf8-e053-d805fe0aa794
|
125
|
|
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA, file e0d6c929-f65c-fcf8-e053-d805fe0aa794
|
120
|
|
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer, file e0d6c929-bf6d-fcf8-e053-d805fe0aa794
|
116
|
|
Sunitinib in metastatic renal cell carcinoma: The pharmacological basis of the alternative 2/1 schedule, file e0d6c929-8a7d-fcf8-e053-d805fe0aa794
|
115
|
|
Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells, file e0d6c92b-9bed-fcf8-e053-d805fe0aa794
|
115
|
|
Lessons from the first ecancer symposium on angiogenesis in gastric cancer, file e0d6c927-3a69-fcf8-e053-d805fe0aa794
|
113
|
|
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer, file e0d6c92b-0288-fcf8-e053-d805fe0aa794
|
98
|
|
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment, file e0d6c92a-0b5b-fcf8-e053-d805fe0aa794
|
96
|
|
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia, file e0d6c92b-0633-fcf8-e053-d805fe0aa794
|
90
|
|
null, file e0d6c927-e576-fcf8-e053-d805fe0aa794
|
85
|
|
Implications of KRAS mutations in acquired resistance to treatment in NSCLC, file e0d6c929-b8bf-fcf8-e053-d805fe0aa794
|
79
|
|
null, file e0d6c929-96d6-fcf8-e053-d805fe0aa794
|
74
|
|
A new HPLC-UV method compared with HPLC-MS for daptomycin levels in human plasma samples, file e0d6c92e-e5f1-fcf8-e053-d805fe0aa794
|
73
|
|
KRAS has a role in acquired resistance to EGFR-TKIs in NSCLC: an analysis on circulating tumor DNA, file e0d6c927-4b88-fcf8-e053-d805fe0aa794
|
71
|
|
Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting, file e0d6c929-96a6-fcf8-e053-d805fe0aa794
|
59
|
|
Radiomics and liquid biopsy in oncology: the holons of systems medicine, file e0d6c92b-0966-fcf8-e053-d805fe0aa794
|
59
|
|
DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis., file e0d6c926-3f25-fcf8-e053-d805fe0aa794
|
53
|
|
A new HPLC-UV method compared with HPLC-MS for daptomycin levels in human plasma samples, file e0d6c92e-1c3e-fcf8-e053-d805fe0aa794
|
53
|
|
Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study, file e0d6c931-26f8-fcf8-e053-d805fe0aa794
|
48
|
|
Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-fluorouracil Antitumor Activity In Vitro and In Vivo, file e0d6c92b-15e7-fcf8-e053-d805fe0aa794
|
37
|
|
Determination of mitotane and principal metabolite by a simple HPLC-UV method and its validation in human plasma sample, file e0d6c92d-c683-fcf8-e053-d805fe0aa794
|
36
|
|
Determination of Mitotane (DDD) and Principal Metabolite by a Simple HPLC-UV Method and Its Validation in Human Plasma Samples, file e0d6c931-171a-fcf8-e053-d805fe0aa794
|
33
|
|
Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence, file e0d6c932-14cf-fcf8-e053-d805fe0aa794
|
31
|
|
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer, file e0d6c932-01b0-fcf8-e053-d805fe0aa794
|
30
|
|
Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small cell lung cancer cells, file e0d6c926-39a0-fcf8-e053-d805fe0aa794
|
29
|
|
null, file e0d6c927-4b86-fcf8-e053-d805fe0aa794
|
27
|
|
KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges, file e0d6c92f-3a16-fcf8-e053-d805fe0aa794
|
27
|
|
Hematologic toxicity of immunosuppressive treatment, file e0d6c926-21a0-fcf8-e053-d805fe0aa794
|
26
|
|
Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines, file e0d6c926-2108-fcf8-e053-d805fe0aa794
|
24
|
|
Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma, file e0d6c92d-5c21-fcf8-e053-d805fe0aa794
|
24
|
|
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy, file e0d6c925-ef35-fcf8-e053-d805fe0aa794
|
23
|
|
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine, file e0d6c92a-07c7-fcf8-e053-d805fe0aa794
|
23
|
|
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients, file 36a8d48f-2872-4e81-b895-4f8eb382b5ba
|
17
|
|
REDUCED CARDIOTOXICITY AND INCREASED CYTOTOXICITY IN A NOVEL ANTHRACYCLINE ANALOG, 4'-AMINO-3'-HYDROXY-DOXORUBICIN, file e0d6c926-3348-fcf8-e053-d805fe0aa794
|
17
|
|
DPYD c.1905+1G>A and c.2846 A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer., file e0d6c92b-676c-fcf8-e053-d805fe0aa794
|
17
|
|
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients, file e0d6c931-b619-fcf8-e053-d805fe0aa794
|
16
|
|
Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications, file e0d6c926-3f26-fcf8-e053-d805fe0aa794
|
14
|
|
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC, file e0d6c92f-d61a-fcf8-e053-d805fe0aa794
|
14
|
|
Polycomb genes and cancer: time for clinical application?, file e0d6c926-181c-fcf8-e053-d805fe0aa794
|
13
|
|
Genetic variation: effect on prostate cancer, file e0d6c927-4622-fcf8-e053-d805fe0aa794
|
12
|
|
Antimicrobial peptides: therapeutic potential for the treatment of Candida infections., file e0d6c929-85a5-fcf8-e053-d805fe0aa794
|
12
|
|
Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer, file e0d6c931-86aa-fcf8-e053-d805fe0aa794
|
12
|
|
Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A (DZNeP) with gemcitabine in pancreatic cancer cells, file e0d6c926-17a8-fcf8-e053-d805fe0aa794
|
11
|
|
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer, file e0d6c92a-065f-fcf8-e053-d805fe0aa794
|
11
|
|
VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration, file e0d6c926-38de-fcf8-e053-d805fe0aa794
|
9
|
|
Refining sorafenib therapy: lessons from clinical practice, file e0d6c927-3766-fcf8-e053-d805fe0aa794
|
9
|
|
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo, file e0d6c926-4180-fcf8-e053-d805fe0aa794
|
8
|
|
Pharmacogenomics and cancer stem cells: a changing landscape?, file e0d6c929-a0c1-fcf8-e053-d805fe0aa794
|
8
|
|
Teratogenesis and immunosuppressive treatment, file e0d6c926-26cd-fcf8-e053-d805fe0aa794
|
7
|
|
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo, file e0d6c926-4715-fcf8-e053-d805fe0aa794
|
7
|
|
Predicting Fluoropyrimidine-Related Toxicity: Turning Wish to Will, The Pamm-Eortc Position, file e0d6c92a-cbc3-fcf8-e053-d805fe0aa794
|
7
|
|
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients, file e0d6c92b-384d-fcf8-e053-d805fe0aa794
|
7
|
|
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer, file e0d6c931-4606-fcf8-e053-d805fe0aa794
|
7
|
|
Liquid biopsies from pleural effusions and plasma from patients with malignant pleural mesothelioma: A feasibility study, file e0d6c931-9b91-fcf8-e053-d805fe0aa794
|
7
|
|
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study, file e0d6c926-284d-fcf8-e053-d805fe0aa794
|
6
|
|
Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro, file e0d6c926-470f-fcf8-e053-d805fe0aa794
|
6
|
|
Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro, file e0d6c92a-d124-fcf8-e053-d805fe0aa794
|
6
|
|
CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone, file e0d6c92f-4c78-fcf8-e053-d805fe0aa794
|
6
|
|
Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers, file e0d6c92f-b519-fcf8-e053-d805fe0aa794
|
6
|
|
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients, file e0d6c931-58b6-fcf8-e053-d805fe0aa794
|
6
|
|
Fructose-1,6-diphosphate reduces acute ECG changes due to doxorubicin in isolated rat heart, file e0d6c925-e525-fcf8-e053-d805fe0aa794
|
5
|
|
Carbogen and nicotinamide combined with
unconventional radiotherapy in glioblastoma multiforme: a new modality treatment, file e0d6c925-eb1d-fcf8-e053-d805fe0aa794
|
5
|
|
Geranylgeraniol
overcomes the block of cell proliferation by lovastatin in C6 glioma cells, file e0d6c925-eb7c-fcf8-e053-d805fe0aa794
|
5
|
|
Different recommendations for daptomycin dosing over time in patients with severe infections, file e0d6c926-4284-fcf8-e053-d805fe0aa794
|
5
|
|
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan, file e0d6c926-4717-fcf8-e053-d805fe0aa794
|
5
|
|
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients, file e0d6c927-f523-fcf8-e053-d805fe0aa794
|
5
|
|
Polycomb genes are associated with response to imatinib in chronic myeloid leukemia, file e0d6c928-259b-fcf8-e053-d805fe0aa794
|
5
|
|
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia, file e0d6c929-02ff-fcf8-e053-d805fe0aa794
|
5
|
|
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer., file e0d6c929-d629-fcf8-e053-d805fe0aa794
|
5
|
|
Case report of a successful treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and MRSA/vancomycin-resistant Enterococcus faecium cholecystitis by daptomycin, file e0d6c92a-a29f-fcf8-e053-d805fe0aa794
|
5
|
|
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers, file e0d6c92a-b1ad-fcf8-e053-d805fe0aa794
|
5
|
|
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC), file e0d6c925-eae8-fcf8-e053-d805fe0aa794
|
4
|
|
Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells, file e0d6c925-eb07-fcf8-e053-d805fe0aa794
|
4
|
|
The pharmacological bases of the antiangiogenic activity of paclitaxel, file e0d6c926-17b6-fcf8-e053-d805fe0aa794
|
4
|
|
Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients, file e0d6c926-1cad-fcf8-e053-d805fe0aa794
|
4
|
|
Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg, file e0d6c926-212c-fcf8-e053-d805fe0aa794
|
4
|
|
Pathophysiology and pharmacological targets of VEGF in diabetic macular edema, file e0d6c926-d7ce-fcf8-e053-d805fe0aa794
|
4
|
|
ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview, file e0d6c928-3660-fcf8-e053-d805fe0aa794
|
4
|
|
null, file e0d6c929-b0d0-fcf8-e053-d805fe0aa794
|
4
|
|
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response, file e0d6c92b-0ec5-fcf8-e053-d805fe0aa794
|
4
|
|
Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms, file e0d6c92b-6a5f-fcf8-e053-d805fe0aa794
|
4
|
|
Procedimento attuato per mezzo di un elaboratore per la determinazione dei tempi di ritenzione e dei valori di concentrazione di analiti in una miscela, file e0d6c931-9919-fcf8-e053-d805fe0aa794
|
4
|
|
Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane, file e0d6c925-e7fb-fcf8-e053-d805fe0aa794
|
3
|
|
In vitro studies on gemcitabine combinations with other antiblastics, file e0d6c925-f648-fcf8-e053-d805fe0aa794
|
3
|
|
INVOLVEMENT OF BASIC FIBROBLAST GROWTH-FACTOR IN SURAMIN-INDUCED INHIBITION OF V79/AP4 FIBROBLAST CELL-PROLIFERATION, file e0d6c926-1c16-fcf8-e053-d805fe0aa794
|
3
|
|
Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas, file e0d6c926-1f7e-fcf8-e053-d805fe0aa794
|
3
|
|
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study, file e0d6c926-22c9-fcf8-e053-d805fe0aa794
|
3
|
|
Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1, file e0d6c926-2507-fcf8-e053-d805fe0aa794
|
3
|
|
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1., file e0d6c926-37ee-fcf8-e053-d805fe0aa794
|
3
|
|
Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections, file e0d6c926-3f00-fcf8-e053-d805fe0aa794
|
3
|
| Totale |
4.611 |